[1] Sharma N, Anders H J, Gaikwadd A B. Fiend and friend in the renin angiotensin system: an insight on acute kidney injury [J]. Biomed Pharmacother, 2019, 110: 764-774.
[2] Susantitaphong P, Cruz D N, Cerda J, et al. World incidence of AKI: a meta-analysis [J]. Clin J Am Soc Nephrol, 2013, 8(9): 1482-1493.
[3] Ostermamn M, Liu K. Pathophysiology of AKI [J]. Best Pract Res Clin Anaesthesiol, 2017, 31(3): 305-314.
[4] Khreba N A, Abdelsalam M, Wahab A M, et al. Kidney injury molecule 1 (KIM-1) as an early predictor for acute kidney injury in post-cardiopulmonary bypass (CPB) in open heart surgery patients [J]. Int J Nephrol, 2019, 2019: 6265307.
[5] Hobson C, Ruchi R, Bihorac A. Perioperative acute kidney injury: risk factors and predictive strategies [J]. Crit Care Clin, 2017, 33(2): 379-396.
[6] Ba Aqeel S H, Sanchez A, Batlle D. Angiotensinogen as a biomarker of acute kidney injury [J]. Clin Kidney J, 2017, 10(6): 759-768.
[7] Dudoignon E, Moreno N, Deniau B, et al. Activation of the renin-angiotensin-aldosterone system is associated with acute kidney injury in COVID-19 [J]. Anaesth Crit Care Pain Med, 2020, 39(4): 453-455.
[8] Cheungpasitporn W, Thongprayoon C, Srivali N, et al. Preoperative renin-angiotensin system inhibitors use linked to reduced acute kidney injury: a systematic review and meta-analysis [J]. Nephrol Dial Transplant, 2015, 30(6): 978-988.
[9] Hsu C Y, Liu K D, Yang J, et al. Renin-angiotensin system blockade after acute kidney injury (AKI) and risk of recurrent AKI [J]. Clin J Am Soc Nephro, 2020, 15(1): 26-34.
[10] IwaI M, Horiuchi M. Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis [J]. Hypertens Res, 2009, 32(7): 533-536.
[11] 蒋 蕾. 尿肾素对危重症患儿急性肾损伤的早期预测价值及与预后的相关性研究 [D]. 苏州: 苏州大学, 2020.
[12] Kobori H, Nangaku M, Navar L G, et al. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease [J]. Pharmacol Rev, 2007, 59(3): 251-287.
[13] van den Heuvel M, Batenburg W W, Jainandunsing S, et al. Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney [J]. J Hypertens, 2011, 29(11): 2147-2155.
[14] Kuai Y, Huang H, Dai X, et al. In PICU acute kidney injury stage 3 or mortality is associated with early excretion of urinary renin [J]. Pediatr Res, 2022, 91(5): 1149-1155.
[15] Stanski N L, Pode Shakked N, Zhang B, et al. Serum renin and prorenin concentrations predict severe persistent acute kidney injury and mortality in pediatric septic shock [J]. Pediatr Nephrol, 2023, 38(9): 3099-3108.
[16] Küllmar M, Saadat-gilani K, Weiss R, et al. Kinetic changes of plasma renin concentrations predict acute kidney injury in cardiac surgery patients [J]. Am J Respir Crit Care Med, 2021, 203(9): 1119-1126.
[17] Flannery A H, Ortiz-soriano V, Li X, et al. Serum renin and major adverse kidney events in critically ill patients: a multicenter prospective study [J]. Crit Care, 2021, 25(1): 294.
[18] Sun C Y, Cherng W J, Jian H Z, et al. Aliskiren reduced renal fibrosis in mice with chronic ischemic kidney injury-beyond the direct renin inhibition [J]. Hypertens Res, 2012, 35(3): 304-311.
[19] Sparks M A, Crowley S D, Gurley S B, et al. Classical renin-angiotensin system in kidney physiology [J]. Compr Physiol, 2014, 4(3): 1201-1228.
[20] 赵 娜, 邱国萍, 赵云艽. 尿血管紧张素原在CRRT治疗急性肾损伤中的预测作用 [J]. 中国现代医生, 2021, 59(19): 53-55,59.
[21] Dou Y, Song D, Wang C, et al. The role of urinary angiotensinogen in kidney interstitial inflammation and renal prognosis [J]. Iran J Kidney Dis, 2019, 13(6): 372-379.
[22] Chen C, Yang X, Lei Y, et al. Urinary biomarkers at the time of AKI diagnosis as predictors of progression of AKI among patients with acute cardiorenal syndrome [J]. Clin J Am Soc Nephrol, 2016, 11(9): 1536-1544.
[23] Yang X, Chen C, Tian J, et al. Urinary angiotensinogen level predicts AKI in acute decompensated heart failure: a prospective, two-stage study [J]. J Am Soc Nephrol, 2015, 26(8): 2032-2041.
[24] Cui S, Wu L, Feng X, et al. Urinary angiotensinogen predicts progressive chronic kidney disease after an episode of experimental acute kidney injury [J]. Clin Sci (Lond), 2018, 132(19): 2121-2133.
[25] Alge J L, Karakala N, Neely B A, et al. Urinary angiotensinogen and risk of severe AKI [J]. Clin J Am Soc Nephrol, 2013, 8(2): 184-193.
[26] Alge J L, Karakala N, Neely B A, et al. Urinary angiotensinogen predicts adverse outcomes among acute kidney injury patients in the intensive care unit [J]. Crit Care, 2013, 17(2): R69.
[27] Kashani K, Cheungpasitporn W, Ronco C. Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption [J]. Clin Chem Lab Med, 2017, 55(8): 1074-1089.
[28] Kobori H, Prieto-carrasquero M, Ozawa Y, et al. AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin Ⅱ-dependent hypertension [J]. Hypertension, 2004, 43(5): 1126-1132.
[29] Zhu Y, Xu D, Deng F, et al. Angiotensin (1-7) attenuates sepsis-induced acute kidney injury by regulating the NF-kappaB pathway [J]. Front Pharmacol, 2021, 12: 601909.
[30] Silva L S, Peruchetti D B, Silva-aguiar R P, et al. The angiotensin II/AT1 receptor pathway mediates malaria-induced acute kidney injury [J]. PLoS One, 2018, 13(9): e0203836.
[31] Benedetto U, Sciarretta S, Roscitano A, et al. Preoperative angiotensin-converting enzyme inhibitors and acute kidney injury after coronary artery bypass grafting [J]. Ann Thorac Surg, 2008, 86(4): 1160-1165.
[32] Peng F, Su J, Lin J, et al. Impact of renin-angiotensin-aldosterone system-blocking agents on the risk of contrast-induced acute kidney injury: a prospective study and meta-analysis [J]. J Cardiovasc Pharmacol, 2015, 65(3): 262-268.
[33] Gayat E, Hollinger A, Cariou A, et al. Impact of angiotensin-converting enzyme inhibitors or receptor blockers on post-ICU discharge outcome in patients with acute kidney injury [J]. Intensive Care Med, 2018, 44(5): 598-605.
[34] 王鹤定, 晏焕青, 崔 玲, 等. 脓毒症合并急性肾损伤患者PRA、AngⅡ水平变化 [J]. 热带医学杂志, 2021, 21(1): 87-90.
[35] Nishiyama A, Kim-mitsuyama S. New approaches to blockade of the renin-angiotensin-aldosterone system: overview of regulation of the renin-angiotensin-aldosterone system [J]. J Pharmacol Sci, 2010, 113(4): 289-291.
[36] Blasi E R, Rocha R, Rudolph A E, et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats [J]. Kidney Int, 2003, 63(5): 1791-1800.
[37] Martín-fernández B, Rubio-navarro A, Cortegano I, et al. Aldosterone induces renal fibrosis and inflammatory M1-macrophage subtype via mineralocorticoid receptor in rats [J]. PLoS One, 2016, 11(1): e0145946.
[38] Rafiq K, Hitomi H, Nakano D, et al. Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney [J]. J Pharmacol Sci, 2011, 115(1): 1-7.
[39] 金国萍, 应利君, 童海明, 等. 核受体PPARγ在醛固酮诱导大鼠急性肾损伤中的作用研究 [J]. 浙江医学, 2015, 37(14): 1196-1208.
[40] Abdel-hakeem E A, Abdel Hafez S M N, Kamel B A, et al. Angiotensin 1-7 mitigates rhabdomyolysis induced renal injury in rats via modulation of TLR-4/NF-kB/iNOS and Nrf-2/heme-oxygenase-1 signaling pathways [J]. Life Sci, 2022, 303: 120678.